Vimarsana
Biggest News Aggregation in the World

Page 29 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

WHO Global Arborvirus Initiative: Where do Infectious Disease Providers Play a Role? - Vimarsana News

WHO Global Arborvirus Initiative: Where do Infectious Disease Providers Play a Role?

Karen Kruuger, MD, highlights the need for infectious disease providers to understand the signs and symptoms that require more urgent evaluation among patients infected with arboviruses .

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) - Vimarsana News

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)

/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...

Pemazyre Approved for Certain Myeloid/Lymphoid Neoplasms - Vimarsana News

Pemazyre Approved for Certain Myeloid/Lymphoid Neoplasms

The FDA has approved Pemazyre (pemigatinib) for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer - Vimarsana News

TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer

Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease

New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 - Vimarsana News

New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in...